Obesity and lung cancer - is programmed death ligand-1 (PD-1L) expression a connection?

Jakub Krzysztof Gałązka; Marcin Czeczelewski; Tomasz Kucharczyk; Katarzyna Szklener; Sławomir Mańdziuk

doi:10.5114/aoms/175470

Obesity and lung cancer - is programmed death ligand-1 (PD-1L) expression a connection?

Arch Med Sci. 2024 Jan 12;20(1):313-316. doi: 10.5114/aoms/175470. eCollection 2024.

Authors

Jakub Krzysztof Gałązka¹, Marcin Czeczelewski², Tomasz Kucharczyk³, Katarzyna Szklener⁴, Sławomir Mańdziuk⁴

Affiliations

¹ Students' Scientific Association at Chair of Clinical Oncology and Chemotherapy, Medical University of Lublin, Lublin, Poland.
² Students' Scientific Association at Department and Clinic of Interventional Radiology and Neuroradiology, Medical University of Lublin, Lublin, Poland.
³ Laboratory for Immunology and Genetics, Medical University of Lublin, Lublin, Poland.
⁴ Chair of Clinical Oncology and Chemotherapy, Medical University of Lublin, Lublin, Poland.

Abstract

Introduction: In this retrospective study, the authors evaluated whether obesity-induced immunomodulation impacts the expression of programmed death ligand-1 (PD-1L) in lung cancer cells.Methods: A retrospective cross-sectional study was performed. The study included 67 patients. The data did not have a normal distribution.

Results: For women, using ANOVA test (p = 0.050) with post-hoc analysis, a statistically significant difference in expression was found between women with overweight and women with normal weight (p = 0.040).

Conclusions: Apart from the above, the authors did not find any statistically significant correlation between PD-1L expression on lung cancer cells and body mass index, either in the whole group or in histological subgroups.

Keywords: lung cancer; obesitology; obesity; oncology; programmed death ligand-1; pulmonology.